BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 17637812)

  • 1. Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations: implications for the cell of origin of NPMc+ AML.
    Martelli MP; Manes N; Pettirossi V; Liso A; Pacini R; Mannucci R; Zei T; Bolli N; di Raimondo F; Specchia G; Nicoletti I; Martelli MF; Falini B
    Leukemia; 2008 Jan; 22(1):195-8. PubMed ID: 17637812
    [No Abstract]   [Full Text] [Related]  

  • 2. A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF.
    Bolli N; De Marco MF; Martelli MP; Bigerna B; Pucciarini A; Rossi R; Mannucci R; Manes N; Pettirossi V; Pileri SA; Nicoletti I; Falini B
    Leukemia; 2009 Mar; 23(3):501-9. PubMed ID: 19005479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives.
    Falini B; Sportoletti P; Martelli MP
    Curr Opin Oncol; 2009 Nov; 21(6):573-81. PubMed ID: 19770764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia.
    Falini B; Mecucci C; Saglio G; Lo Coco F; Diverio D; Brown P; Pane F; Mancini M; Martelli MP; Pileri S; Haferlach T; Haferlach C; Schnittger S
    Haematologica; 2008 Mar; 93(3):439-42. PubMed ID: 18268276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
    Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
    Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.
    Falini B; Nicoletti I; Martelli MF; Mecucci C
    Blood; 2007 Feb; 109(3):874-85. PubMed ID: 17008539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML.
    Falini B; Bigerna B; Pucciarini A; Tiacci E; Mecucci C; Morris SW; Bolli N; Rosati R; Hanissian S; Ma Z; Sun Y; Colombo E; Arber DA; Pacini R; La Starza R; Verducci Galletti B; Liso A; Martelli MP; Diverio D; Pelicci PG; Lo Coco F; Martelli MF
    Leukemia; 2006 Feb; 20(2):368-71. PubMed ID: 16341033
    [No Abstract]   [Full Text] [Related]  

  • 8. Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype.
    Luo J; Qi C; Xu W; Kamel-Reid S; Brandwein J; Chang H
    Am J Clin Pathol; 2010 Jan; 133(1):34-40. PubMed ID: 20023256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 mutations in acute myeloid leukaemia.
    Scholl S; Mügge LO; Landt O; Loncarevic IF; Kunert C; Clement JH; Höffken K
    Leuk Res; 2007 Sep; 31(9):1205-11. PubMed ID: 17306368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.
    Cilloni D; Messa F; Rosso V; Arruga F; Defilippi I; Carturan S; Catalano R; Pautasso M; Panuzzo C; Nicoli P; Messa E; Morotti A; Iacobucci I; Martinelli G; Bracco E; Saglio G
    Leukemia; 2008 Jun; 22(6):1234-40. PubMed ID: 18401421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.
    Ovcharenko D; Stölzel F; Poitz D; Fierro F; Schaich M; Neubauer A; Kelnar K; Davison T; Müller-Tidow C; Thiede C; Bornhäuser M; Ehninger G; Brown D; Illmer T
    Exp Hematol; 2011 Oct; 39(10):1030-1042.e7. PubMed ID: 21784052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features.
    Falini B
    Cancer Treat Res; 2010; 145():149-68. PubMed ID: 20306250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia.
    Noguera NI; Ammatuna E; Zangrilli D; Lavorgna S; Divona M; Buccisano F; Amadori S; Mecucci C; Falini B; Lo-Coco F
    Leukemia; 2005 Aug; 19(8):1479-82. PubMed ID: 15973451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoplasmic expression of nucleophosmin 1 as a marker for diagnosing residual disease of acute myeloid leukemia.
    Dai Q; Ren Y
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):205-11. PubMed ID: 23591014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunohistochemical demonstration of mutant nucleophosmin in acute myeloid leukemia: biological and clinical features related to NPMc expression].
    Bedekovics J; Rejto L; Telek B; Udvardy M; Ujfalusi A; Oláh E; Hevessy Z; Kappelmayer J; Kajtár B; Méhes G
    Orv Hetil; 2009 May; 150(22):1031-5. PubMed ID: 19465351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations of NPM1 gene in de novo acute myeloid leukaemia: determination of incidence, distribution pattern and identification of two novel mutations in Indian population.
    Ahmad F; Mandava S; Das BR
    Hematol Oncol; 2009 Jun; 27(2):90-7. PubMed ID: 19365794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations.
    Gorello P; Cazzaniga G; Alberti F; Dell'Oro MG; Gottardi E; Specchia G; Roti G; Rosati R; Martelli MF; Diverio D; Lo Coco F; Biondi A; Saglio G; Mecucci C; Falini B
    Leukemia; 2006 Jun; 20(6):1103-8. PubMed ID: 16541144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice.
    Falini B; Martelli MP; Mecucci C; Liso A; Bolli N; Bigerna B; Pucciarini A; Pileri S; Meloni G; Martelli MF; Haferlach T; Schnittger S
    Haematologica; 2008 May; 93(5):775-9. PubMed ID: 18367491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgH/TCR rearrangements are common in MLL translocated adult AML and suggest an early T/myeloid or B/myeloid maturation arrest, which correlates with the MLL partner.
    Dupret C; Asnafi V; Leboeuf D; Millien C; Ben Abdelali R; Preudhomme C; Beldjord K; Delabesse E; Macintyre E
    Leukemia; 2005 Dec; 19(12):2337-8. PubMed ID: 16304577
    [No Abstract]   [Full Text] [Related]  

  • 20. Rapid flow cytometric detection of aberrant cytoplasmic localization of nucleophosmin (NPMc) indicating mutant NPM1 gene in acute myeloid leukemia.
    Oelschlaegel U; Koch S; Mohr B; Schaich M; Falini B; Ehninger G; Thiede C
    Leukemia; 2010 Oct; 24(10):1813-6. PubMed ID: 20724983
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.